Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
NCT02618577 · Atrial Fibrillation Network · PHASE3 · terminated · last registry update 2025-02-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.” | – | Registry record, Atrial Fibrillation Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-06Results posted on the registry: Lumosa Therapeutics Co., Ltd., LT3001 drug product + Placebo (NCT04809818)
- 2026-01-06Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + REGN9933 (NCT07318610)
- 2025-12-10Also stopped (terminated): CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-14Phase 3 first posted: McMaster University, rivaroxaban and ASA + Low-molecular weight heparin (NCT07228663)
- 2025-11-10Results posted on the registry: CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-06Results posted on the registry: Pfizer, Standard of Care FIX Replacement therapy + Standard of Care FVIII Replacement therapy (NCT03587116)
- 2025-11-04Also stopped (withdrawn): Brian O'Neill MD, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa) (NCT04684212)
- 2025-10-02Phase 3 first posted: Rennes University Hospital, Anticoagulant treatment Rivaroxaban (NCT07202897)
- 2025-09-30Results posted on the registry: Brigham and Women's Hospital, Apixaban 2.5 MG + Placebo oral tablet (NCT04168203)
- 2025-09-08Phase 3 first posted: University of Birmingham, Apixaban (NCT07160686)
- 2025-09-02Results posted on the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., Ciraparantag + Placebo (NCT03172910)
- 2025-09-02Results posted on the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., Ciraparantag + Placebo (NCT03288454)
- 2025-08-15Results posted on the registry: Octapharma, Octaplex + Frozen Plasma Product, Human (NCT05523297)
- 2025-07-30Phase 3 first posted: CSL Behring, BE1116 + FFP (NCT07094087)
- 2025-07-30Results posted on the registry: Anthos Therapeutics, Inc., Abelacimab + Rivaroxaban (NCT04755283)
- 2025-07-16Results posted on the registry: Regeneron Pharmaceuticals, REGN9933 + Enoxaparin (NCT05618808)
- 2025-06-22Results posted on the registry: Stanford University, Apixaban 2.5 MG Oral Tablet + Enoxaparin 40Mg/0.4mL Prefilled Syringe (NCT04504318)
- 2025-06-22Also stopped (terminated): Imperial College London, Best medical therapy (NCT05622500)
- 2025-06-18Results posted on the registry: Fadoi Foundation, Italy, Apixaban + Dalteparin (NCT03045406)
- 2025-06-15Also stopped (terminated): Montreal Heart Institute, Rivaroxaban (NCT02387229)
- 2025-06-11Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + Apixaban (NCT07015905)
- 2025-06-05Results posted on the registry: Takeda, a drug against F10 (NCT05437211)
- 2025-06-04Phase 3 first posted: University of Vermont, Apixaban 2.5 mg twice daily + Apixaban 5 mg once daily (NCT07005024)
- 2025-05-31Phase 3 first posted: Hoffmann-La Roche, Emicizumab + von Willebrand Factor (VWF) Concentrates (NCT06998524)
- 2025-05-11Phase 3 first posted: Ottawa Hospital Research Institute, Full dose rivaroxaban + Low dose rivaroxaban (NCT06965998)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision